- Home
- ARDC vs GOSS Comparison
ARDC vs GOSS Comparison
Compare ARDC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDC
- GOSS
- Stock Information
- Founded
- ARDC 2012
- GOSS 2015
- Country
- ARDC United States
- GOSS United States
- Employees
- ARDC N/A
- GOSS N/A
- Industry
- ARDC Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ARDC Finance
- GOSS Health Care
- Exchange
- ARDC Nasdaq
- GOSS Nasdaq
- Market Cap
- ARDC 344.2M
- GOSS 347.8M
- IPO Year
- ARDC N/A
- GOSS 2019
- Fundamental
- Price
- ARDC $14.71
- GOSS $2.47
- Analyst Decision
- ARDC
- GOSS Strong Buy
- Analyst Count
- ARDC 0
- GOSS 4
- Target Price
- ARDC N/A
- GOSS $8.50
- AVG Volume (30 Days)
- ARDC 115.8K
- GOSS 3.1M
- Earning Date
- ARDC 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- ARDC 9.84%
- GOSS N/A
- EPS Growth
- ARDC N/A
- GOSS N/A
- EPS
- ARDC N/A
- GOSS N/A
- Revenue
- ARDC N/A
- GOSS $40,237,000.00
- Revenue This Year
- ARDC N/A
- GOSS N/A
- Revenue Next Year
- ARDC N/A
- GOSS $30.65
- P/E Ratio
- ARDC N/A
- GOSS N/A
- Revenue Growth
- ARDC N/A
- GOSS N/A
- 52 Week Low
- ARDC $11.56
- GOSS $0.66
- 52 Week High
- ARDC $14.30
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- ARDC 66.23
- GOSS 68.08
- Support Level
- ARDC $14.53
- GOSS $2.38
- Resistance Level
- ARDC $14.64
- GOSS $2.65
- Average True Range (ATR)
- ARDC 0.10
- GOSS 0.15
- MACD
- ARDC 0.00
- GOSS 0.03
- Stochastic Oscillator
- ARDC 100.00
- GOSS 76.67
About ARDC Ares Dynamic Credit Allocation Fund Inc.
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.